All In Biotech

Drug Trial Radar · NCT06787950

Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity of ASN-3186 in Patients with Advanced Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Mar 20, 2029

Study completion Sep 20, 2029

Sponsor

Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • ASN-3186Drug

    ASN-3186 will be administered orally.

  • ASN-3186Drug

    ASN-3186 will be administered orally.

  • ASN-3186Drug

    ASN-3186 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. phase 1( Dose Escalation Stage): Dose Limiting Toxicity (DLT)Time frame: During the first 26 Days
  2. phase 1( Dose Escalation Stage): Recommended phase 2 dose(RP2D)Time frame: 14 months
  3. phase 2a: ORRTime frame: 26 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.